Orchid Pharma Ltd
NSE:ORCHPHARMA
Orchid Pharma Ltd
Income from Continuing Operations
Orchid Pharma Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orchid Pharma Ltd
NSE:ORCHPHARMA
|
Income from Continuing Operations
₹950.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹54.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹50B
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹114.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹18.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Income from Continuing Operations
₹19.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Orchid Pharma Ltd
Glance View
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
See Also
What is Orchid Pharma Ltd's Income from Continuing Operations?
Income from Continuing Operations
950.6m
INR
Based on the financial report for Mar 31, 2024, Orchid Pharma Ltd's Income from Continuing Operations amounts to 950.6m INR.
What is Orchid Pharma Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
6%
Over the last year, the Income from Continuing Operations growth was 72%.
You don't have any saved screeners yet